Financial Performance - The company's operating revenue for Q3 2022 was CNY 3,185,688,204.81, representing a year-on-year increase of 1.66%[2] - Net profit attributable to shareholders for Q3 2022 was CNY 489,254,328.37, reflecting a significant increase of 25.37% compared to the same period last year[2] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 462,530,618.00, up by 9.01% year-on-year[2] - The company's operating revenue for the first nine months of 2022 was RMB 9,488.25 million, a year-on-year increase of 1.27%[8] - The net profit attributable to shareholders for the first nine months of 2022 was RMB 1,506,800,118.40, compared to RMB 1,452,730,415.78 in the previous year, indicating an increase of about 3.73%[17] - The company's total operating profit for the first nine months of 2022 was RMB 1,872,605,981.76, slightly down from RMB 1,874,923,979.34 in the same period of 2021, indicating a decrease of about 0.12%[17] - The total comprehensive income for the period (January to September 2022) was approximately RMB 1.66 billion, an increase from RMB 1.45 billion in the same period of 2021, representing a growth of about 14.2%[18] Assets and Liabilities - The total assets at the end of the reporting period were CNY 23,569,873,466.33, an increase of 5.35% from the end of the previous year[3] - The total equity attributable to shareholders at the end of the reporting period was CNY 13,432,828,237.84, up by 3.30% from the previous year[3] - The total liabilities increased to RMB 9,058,494,489.03 at the end of the reporting period, compared to RMB 8,060,890,797.20 at the beginning of the year, marking an increase of about 12.35%[16] - The company's total non-current liabilities rose to RMB 2,324,476,858.20, compared to RMB 1,135,822,729.96 at the beginning of the year, reflecting an increase of approximately 104.8%[16] Cash Flow - The company's cash flow from operating activities for the period was CNY 1,847,923,769.75, showing a substantial increase of 41.57% year-on-year[2] - The net cash flow from operating activities rose by 41.57% to RMB 1,847.92 million, driven by increased sales receipts and reduced marketing expenses[9] - The net cash flow from investing activities was negative RMB 769 million, an improvement from negative RMB 1.37 billion in the same period of 2021[19] - The net cash flow from financing activities was negative RMB 757 million, which is an improvement compared to negative RMB 898 million in the previous year[20] Shareholder Information - The company had a total of 67,097 common shareholders at the end of the reporting period[10] - The company has a significant shareholder structure, with Hong Kong Central Clearing (Agent) Limited holding 309,562,240 shares, representing a major portion of the equity[12] - Health元药业集团股份有限公司 holds 221,376,789 shares, indicating its substantial stake in the company[12] Revenue Breakdown - The revenue from chemical products was RMB 5,571.60 million, a decrease of 3.40% year-on-year, with digestive products declining by 11.60%[8] - The revenue from raw materials and intermediates increased by 15.99% to RMB 2,499.26 million, indicating strong demand in this segment[8] Other Comprehensive Income - The company reported a significant increase in other comprehensive income after tax, rising by 163.56% to RMB 100.29 million, mainly due to foreign exchange fluctuations[8] - The company’s other comprehensive income attributable to shareholders of the parent company was RMB 97.61 million, a significant recovery from a loss of RMB 157.51 million in the same period of 2021[18] Research and Development - Research and development expenses for the first nine months of 2022 amounted to RMB 978,746,743.57, up from RMB 786,282,945.23 in the same period last year, reflecting a growth of approximately 24.5%[17] - The company is focused on expanding its market presence and enhancing its product offerings through ongoing research and development initiatives[15]
丽珠医药(01513) - 2022 Q3 - 季度财报